MedTrace Logo

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

NCT01525082 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-02-06

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to evaluate the effectiveness and safety of a combination of capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic neuroendocrine tumors.

Conditions

  • Gastrinoma
  • Glucagonoma
  • Insulinoma
  • Pancreatic Polypeptide Tumor
  • Recurrent Islet Cell Carcinoma
  • Recurrent Pancreatic Cancer
  • Somatostatinoma
  • Stage III Pancreatic Cancer
  • Stage IV Pancreatic Cancer

Interventions

DRUG

Capecitabine

Capecitabine by mouth twice daily on Days 1 to 14

DRUG

Temozolomide

Temozolomide by mouth daily on Days 10 to 14

BIOLOGICAL

Bevacizumab

Bevacizumab IV over 30 to 90 minutes on Days 1 \& 15

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Shaheen Shagufta

    lead OTHER

Principal Investigators

  • Shaheen Shagufta, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2018-01-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01525082 on ClinicalTrials.gov